Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 16/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6979710 | 0.89 | NR3C1 (0.41) | NR3C1BRD4CREBBPTRIM24 | |
| Hydrochloric Acid SCHEMBL6977752 | 0.84 | F2 (0.49) | NR3C1BRD4CREBBP | |
| Hydrochloric Acid SCHEMBL6977280 | 0.81 | NR3C1 (0.61) | NR3C1SMN1; SMN2 | |
| SCHEMBL6978010 | 0.81 | BRD4 (0.54) | NR3C1BRD4CREBBPSMN1; SMN2 | |
| SCHEMBL6982740 | 0.81 | NR3C1 (0.59) | NR3C1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6981078 | 0.80 | NR3C1 (0.58) | NR3C1SMN1; SMN2 | |
| SCHEMBL6982230 | 0.80 | NR3C1 (0.47) | NR3C1BRD4CREBBPTRIM24SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6982102 | 0.80 | NR3C1 (0.48) | NR3C1BRD4CREBBPSMN1; SMN2 | |
| Iodide SCHEMBL7959251 | 0.80 | NR3C1 (0.48) | NR3C1BRD4CREBBPSMN1; SMN2 | |
| SCHEMBL6979627 | 0.79 | NR3C1 (0.46) | NR3C1BRD4CREBBPTRIM24SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0991624-B1 | PHENYLALKYL DERIVATIVES WITH THROMBIN-INHIBITING EFFECT | BOEHRINGER INGELHEIM PHARMA (DE) | 2003-11-19 | — | — | EP | disclosed |
| US-6300342-B1 | FOR THERAPY OR INHIBITING THROMBUS FORMATION; FOR THERAPY OF FIBRIN-DEPENDENT INFLAMMATORY CONDITION | BOEHRINGER INGELHEIM PHARM KG (DE) | 2001-10-09 | — | — | US | disclosed |